A genome-wide association study suggests new susceptibility loci for primary antiphospholipid syndrome

1Division of Rheumatology, Department of Pediatrics, University of Pittsburgh, Pittsburgh, USA;

2Genetics of Complex Diseases Group, Department of Genomic Medicine, GENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, Granada, Spain;

3Division of Rheumatology, Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy; Immunorheumatology research laboratory – IRCCS Istituto Auxologico Italiano, Milan, Italy;

4Department of Autoimmune Diseases, Reference Centre for Systemic Autoimmune Diseases (UEC/CSUR) of the Catalan and Spanish Health Systems-Member of ERN-ReCONNET, Hospital Clínic, Universitat de Barcelona, Barcelona, Catalonia, Spain;

5Cambridge Institute of Therapeutic Immunology & Infectious Disease, Jeffrey Cheah Biomedical Centre, Cambridge Biomedical Campus, University of Cambridge, Puddicombe Way, Cambridge CB2 0AW, UK; Department of Medicine, University of Cambridge School of Clinical Medicine, Cambridge Biomedical Campus, Cambridge CB2 0QQ, UK;

6Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA;

4Department of Autoimmune Diseases, Reference Centre for Systemic Autoimmune Diseases (UEC/CSUR) of the Catalan and Spanish Health Systems-Member of ERN-ReCONNET, Hospital Clínic, Universitat de Barcelona, Barcelona, Catalonia, Spain;

7Laboratory for Translational Immunology and Department of Pediatric Rheumatology and Immunology, University Medical Center Utrecht, Utrecht, the Netherlands; Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, the Netherlands;

8Department of Rheumatology, Radboudumc and Sint Maartenskliniek, Nijmegen, The Netherlands;

9Cambridge Institute of Therapeutic Immunology & Infectious Disease, Jeffrey Cheah Biomedical Centre, Cambridge Biomedical Campus, University of Cambridge, Puddicombe Way, Cambridge CB2 0AW, UK; Department of Medicine, University of Cambridge School of Clinical Medicine, Cambridge Biomedical Campus, Cambridge CB2 0QQ, UK; MRC Biostatistics Unit, University of Cambridge, Cambridge Institute of Public Health, Forvie Site, Robinson Way, Cambridge Biomedical Campus, Cambridge CB2 0SR, UK;

10Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA;

10Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA;

4Department of Autoimmune Diseases, Reference Centre for Systemic Autoimmune Diseases (UEC/CSUR) of the Catalan and Spanish Health Systems-Member of ERN-ReCONNET, Hospital Clínic, Universitat de Barcelona, Barcelona, Catalonia, Spain;

11Immunorheumatology research laboratory – IRCCS Istituto Auxologico Italiano, Milan, Italy;

12Institute of Parasitology and Biomedicine “López-Neyra”, CSIC, Granada, Spain;

6Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA;

2Genetics of Complex Diseases Group, Department of Genomic Medicine, GENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, Granada, Spain;

13Departments of Pediatrics, Medicine, and Immunology & Lupus Center of Excellence, University of Pittsburgh, Pittsburgh, USA